🇺🇸 FDA
Patent

US 9333244

Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia

granted A61KA61K38/47A61K9/0034

Quick answer

US patent 9333244 (Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia) held by HALOZYME, INC. expires Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
HALOZYME, INC.
Grant date
Tue May 10 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
72
CPC classes
A61K, A61K38/47, A61K9/0034, A61K9/127, A61P